An international expert group convened by the American Diabetes Association proposed that the criterion for diabetes remission be an HbA1c level below 6.5%, measured at least three months after glucose-lowering drugs are stopped.
In a cross-sectional survey at an Ohio health system, 67% of respondents with non-insulin-controlled type 2 diabetes said they monitored their blood glucose levels because their physician had asked them to, and 50% said they would stop if given permission.
In a systematic review and meta-analysis of eight randomized controlled trials, glucagon-like peptide-1 (GLP-1) receptor agonists reduced major adverse cardiovascular events by 14%, all-cause mortality by 12%, hospital admission for heart failure by 11%, and a composite kidney outcome by 21%, with no increase in safety outcomes.
This month's quiz asks readers to choose a preventive regimen for a 44-year-old woman with type 2 diabetes, hypertension, and a triglyceride level of 165 mg/dL (1.86 mmol/L).
One review looked at rates of sleep disorders in patients with diabetes, another study found that the combination of impaired glucose tolerance and a sleep disorder increases mortality risk, and patient interviews revealed benefits and barriers to use of continuous positive airway pressure.
Primary care clinicians should screen all overweight or obese adults ages 35 to 70 years for diabetes and prediabetes and should offer interventions for those with either condition, the U.S. Preventive Services Task Force (USPSTF) recently recommended.
Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM
A recent Italian trial showed that regimens with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) or a sodium-glucose cotransporter 2 (SGLT2) inhibitor resulted in less hypoglycemia, but the results may not apply to patients with higher HbA1c levels, an ACP Journal Club commentary said.